Browsing by Author "Pai, V V"
Now showing 1 - 7 of 7
Results Per Page
Sort Options
Item Bowen's disease over the abdomen - A histological pigmented variety.(2011-01) Pai, V V; Hanumanthayya, K; Naveen, K N; Rao, R; Dinesh, U SItem Could ingenol mebutate be useful in managing nonmelanoma skin cancers.(2015-04) Bhandari, P R; Pai, V VItem Disability prevention and management in leprosy: a field experience.(2003-11-24) Ganapati, R; Pai, V V; Kingsley, SBombay Leprosy Project has conducted operational research into cost effective ways of using therapeutic management for prevention of disabilities (POD). The goal of achieving this are broadly divided as 1) prevention of impairments and disabilities [POID] and 2) prevention of worsening of disabilities [POWD]. About 33-56% of newly registered leprosy patients already have clinically detectable nerve function impairment [NFI], often no longer amenable to MDT. An analysis of 892 leprosy cases treated with WHO-MDT stresses the need to focus attention on leprosy patients having > 5 skin lesions and multiple nerve thickening. Assessment of 454 disabled leprosy patients after 4 years indicated that the compliance for the services offered was good and it helped to improve the disability status in more than 50% of patients. In terms of effectiveness of the services, it was found to be effective in preventing worsening of deformities in hands and healing of trophic ulcers in feet. The methodology adopted has also helped us to develop an operational research model about the necessity to systematize the assistance and support to be given if the services can be routed through a public health facility. Because of the large numbers of leprosy patients with disability living in this region and the limited resources available, the services have to be targeted towards those who are most in need. The major advantage of such community based program is an attempt to eliminate the social stigma in the patients' families and the education of the community.Item Granuloma regression after fixed duration therapy.(1998-07-05) Salunkhe, S R; Pai, V V; Ganapati, RItem Hyperpigmented mycosis fungoides with ecthyma gangrenosum.(2015-01) Pai, V V; Kikkeri, N N; Athanikar, S C; Rai, V; Dinesh, U SItem Reactions and their management.(2004-12-06) Ganapati, R; Pai, V VThe uneventful response to chemotherapy in leprosy is marked by clinically disturbing episodes encountered in 20-30% of patients and these phenomena are called "reactions". Generally they are classified as reversal reaction (type-1) and erythema nodosum leprosum (type-2). The cutaneous menifestations are: (1) Type-2 reactions in LL, BL types constituting erythema nodosum leprosum, erythema multiforme, erythema necroticans, subcutaneous nodules, lepromatous exacerbation. (2) Type-1 reactions in borderline and tuberculoid leprosy. The other manifestations include: Acute neuritis, lymphadenitis, arthritis, oedema of the hands and feet, ocular lesions, etc. Sequelae of reactions are: Paralytic deformities, non-paralytic deformities, extensive scarring and renal damage. A simple guideline to identify the risk-prone cases has been narrated. Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes.Item Whither "world without leprosy"?(2005-11-06) Ganapati, R; Pai, V V